The Role of Valacyclovir on Epstein-Barr Virus Viral Loads in Pediatric Liver Transplantation Patients

Transplantation Proceedings

Volumn 41, Issue 7, 2009, Pages 2878-2880

  Ozcay F ^a   Arslan, H ^a   Bilezikci B ^a   Sevmiş, Ş ^a   Moray, G ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; VALACICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; BLOOD; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HETEROZYGOTE; HUMAN; INFANT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ACUTE DISEASE; ACYCLOVIR; ANTIVIRAL AGENTS; BODY WEIGHT; CHILD, PRESCHOOL; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; INFANT; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; VALINE; VIRAL LOAD; VIRUS ACTIVATION;

EID: 70149102671     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.07.059     Document Type: Article

References (10)

1. Breinig M.K., Zitelli B., Starzl T.E., et al. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 156 (1987) 273
2. Cacciarelli T.V., Reyes J., Jaffe R., et al. Primary tacrolimus therapy and the long term risk of post transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transpl 5 (2001) 359
3. Guthery S.L., Heubi J.E., Bucuvalas J.C., et al. Determination of risk factors for Epstein-Barr virus associated post transplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 15 (2003) 987
4. D'Antiga L., del Rizzo M., Mengoli C., et al. Sustained Epstein-Barr virus detection in pediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 13 (2007) 343
5. Sun H.Y., and Singh N. Pharmacotherapy of post-transplant viral infections. Expert Opin Pharmacother 9 (2008) 2409
6. Balfour H.H., Hokanson K.M., Schacherer R.M., et al. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol 39 (2007) 16
7. Nadal D., Leverger G., Sokal E.M., et al. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J Infect Dis 186 suppl 1 (2002) S123
8. Simon M.W., Fish D.N., and Deeter R.G. Pharmacokinetics and safety of Valacyclovir in children with Epstein-Barr virus illness. Drugs RD 3 (2002) 365
9. Bingler M.A., Feingold B., Miller S.A., et al. Chronic high Epstein-Barr viral load state and risk for late-onset PTLD/lymphoma in children. Am J Transplant 8 (2008) 442
10. Hierro L., Diez Dorado R., and Diaz C. Efficacy and safety of valgancyclovir in liver transplanted children infected with Epstein-Barr virus. Liver Transpl 14 (2008) 1185